Category

World News

New Single-Tablet Regimen: FDA Approves Triumeq

ViiV Healthcare’s single-tablet regimen Triumeq won Food and Drug Administration approval on August 22, 2014. Triumeq is the first FDA-approved single-tablet regimen (STR) that does not contain tenofovir (Viread), a widely used antiretroviral drug linked with bone and kidney problems in some susceptible HIV-positive individuals.

STUDY: Tivicay Surpresses HIV Even in Those Who are Drug Resistant

Tivicay, the recently approved HIV integrase inhibitor — a class of antiretroviral drug that is designed to block a virus from entering the DNA of a host cell — demonstrated high rates of viral suppression in a recent study. Significantly, Tivicay is also proven effective for people who are resistant to HIV antiretroviral drugs, according to NAM.